With newly available preliminary efficacy results of surrogate biomarkers, we consider initiating discussions with regulatory agencies for the Accelerated Approval Pathway for ANAVEX2-73. In parallel, we plan to proceed with the initiation of our confirmatory Alzheimer’s disease study.
Facts are important to note also as a biotech investor and indeed to avoid suspicions that people deliberately lie to pee on your sugar sandwich dreams.